- call +1-201-465-4211
- email sales@mrinsights.biz
Primary sclerosing cholangitis (PSC) is a condition causing long-term inflammation and scarring (fibrosis) of bile ducts in the liver. These ducts are tubes that allow the liquid (bile) produced by the liver to pass through the intestine allowing fat digestion. This disease predominantly affects men between the age of 25 and 40 years. The damage to the ducts causes accumulation of bile acids, essential components of bile to build up in the liver leading to liver tissue damage, portal hypertension (high blood pressure in the vessels connecting the liver and the gut), and liver failure, and may increase the risk of liver cancer.
Scope of the Report:
Requirement of providing affordable treatment, owing to high costs associated with liver transplantation coupled with increasing risk factors resulting in the development of serious disorders are major factors that are expected to increase the adoption of PSC drugs, in turn favoring market growth in the near future.
The global Primary Sclerosing Cholangitis market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Primary Sclerosing Cholangitis.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
This report studies the Primary Sclerosing Cholangitis market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Primary Sclerosing Cholangitis market by product type and applications/end industries.
Market Segment by Companies, this report covers
Acorda Therapeutics, Inc.
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.
Shire Plc.
NGM Biopharmaceuticals, Inc.
Dr. Falk Pharma GmbH
Allergan Plc.
Conatus Pharmaceuticals, Inc.
Durect Corporation
Sirnaomics, Inc.
Shenzhen HighTide Biopharmaceuticals Ltd.
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Type I
Type II
Market Segment by Applications, can be divided into
Hospital
Clinics
Other
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Primary Sclerosing Cholangitis Market Overview
1.1 Product Overview and Scope of Primary Sclerosing Cholangitis
1.2 Classification of Primary Sclerosing Cholangitis by Types
1.2.1 Global Primary Sclerosing Cholangitis Revenue Comparison by Types (2017-2023)
1.2.2 Global Primary Sclerosing Cholangitis Revenue Market Share by Types in 2017
1.2.3 Type I
1.2.4 Type II
1.3 Global Primary Sclerosing Cholangitis Market by Application
1.3.1 Global Primary Sclerosing Cholangitis Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Other
1.4 Global Primary Sclerosing Cholangitis Market by Regions
1.4.1 Global Primary Sclerosing Cholangitis Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Primary Sclerosing Cholangitis Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Primary Sclerosing Cholangitis Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Primary Sclerosing Cholangitis Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Primary Sclerosing Cholangitis Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Primary Sclerosing Cholangitis Status and Prospect (2013-2023)
1.5 Global Market Size of Primary Sclerosing Cholangitis (2013-2023)
2 Manufacturers Profiles
2.1 Acorda Therapeutics, Inc.
2.1.1 Business Overview
2.1.2 Primary Sclerosing Cholangitis Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Acorda Therapeutics, Inc. Primary Sclerosing Cholangitis Revenue, Gross Margin and Market Share (2016-2017)
2.2 Gilead Sciences, Inc.
2.2.1 Business Overview
2.2.2 Primary Sclerosing Cholangitis Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Gilead Sciences, Inc. Primary Sclerosing Cholangitis Revenue, Gross Margin and Market Share (2016-2017)
2.3 Intercept Pharmaceuticals, Inc.
2.3.1 Business Overview
2.3.2 Primary Sclerosing Cholangitis Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Intercept Pharmaceuticals, Inc. Primary Sclerosing Cholangitis Revenue, Gross Margin and Market Share (2016-2017)
2.4 Shire Plc.
2.4.1 Business Overview
2.4.2 Primary Sclerosing Cholangitis Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Shire Plc. Primary Sclerosing Cholangitis Revenue, Gross Margin and Market Share (2016-2017)
2.5 NGM Biopharmaceuticals, Inc.
2.5.1 Business Overview
2.5.2 Primary Sclerosing Cholangitis Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 NGM Biopharmaceuticals, Inc. Primary Sclerosing Cholangitis Revenue, Gross Margin and Market Share (2016-2017)
2.6 Dr. Falk Pharma GmbH
2.6.1 Business Overview
2.6.2 Primary Sclerosing Cholangitis Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Dr. Falk Pharma GmbH Primary Sclerosing Cholangitis Revenue, Gross Margin and Market Share (2016-2017)
2.7 Allergan Plc.
2.7.1 Business Overview
2.7.2 Primary Sclerosing Cholangitis Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Allergan Plc. Primary Sclerosing Cholangitis Revenue, Gross Margin and Market Share (2016-2017)
2.8 Conatus Pharmaceuticals, Inc.
2.8.1 Business Overview
2.8.2 Primary Sclerosing Cholangitis Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Conatus Pharmaceuticals, Inc. Primary Sclerosing Cholangitis Revenue, Gross Margin and Market Share (2016-2017)
2.9 Durect Corporation
2.9.1 Business Overview
2.9.2 Primary Sclerosing Cholangitis Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Durect Corporation Primary Sclerosing Cholangitis Revenue, Gross Margin and Market Share (2016-2017)
2.10 Sirnaomics, Inc.
2.10.1 Business Overview
2.10.2 Primary Sclerosing Cholangitis Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Sirnaomics, Inc. Primary Sclerosing Cholangitis Revenue, Gross Margin and Market Share (2016-2017)
2.11 Shenzhen HighTide Biopharmaceuticals Ltd.
2.11.1 Business Overview
2.11.2 Primary Sclerosing Cholangitis Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Shenzhen HighTide Biopharmaceuticals Ltd. Primary Sclerosing Cholangitis Revenue, Gross Margin and Market Share (2016-2017)
3 Global Primary Sclerosing Cholangitis Market Competition, by Players
3.1 Global Primary Sclerosing Cholangitis Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Primary Sclerosing Cholangitis Players Market Share
3.2.2 Top 10 Primary Sclerosing Cholangitis Players Market Share
3.3 Market Competition Trend
4 Global Primary Sclerosing Cholangitis Market Size by Regions
4.1 Global Primary Sclerosing Cholangitis Revenue and Market Share by Regions
4.2 North America Primary Sclerosing Cholangitis Revenue and Growth Rate (2013-2018)
4.3 Europe Primary Sclerosing Cholangitis Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Primary Sclerosing Cholangitis Revenue and Growth Rate (2013-2018)
4.5 South America Primary Sclerosing Cholangitis Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Primary Sclerosing Cholangitis Revenue and Growth Rate (2013-2018)
5 North America Primary Sclerosing Cholangitis Revenue by Countries
5.1 North America Primary Sclerosing Cholangitis Revenue by Countries (2013-2018)
5.2 USA Primary Sclerosing Cholangitis Revenue and Growth Rate (2013-2018)
5.3 Canada Primary Sclerosing Cholangitis Revenue and Growth Rate (2013-2018)
5.4 Mexico Primary Sclerosing Cholangitis Revenue and Growth Rate (2013-2018)
6 Europe Primary Sclerosing Cholangitis Revenue by Countries
6.1 Europe Primary Sclerosing Cholangitis Revenue by Countries (2013-2018)
6.2 Germany Primary Sclerosing Cholangitis Revenue and Growth Rate (2013-2018)
6.3 UK Primary Sclerosing Cholangitis Revenue and Growth Rate (2013-2018)
6.4 France Primary Sclerosing Cholangitis Revenue and Growth Rate (2013-2018)
6.5 Russia Primary Sclerosing Cholangitis Revenue and Growth Rate (2013-2018)
6.6 Italy Primary Sclerosing Cholangitis Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Primary Sclerosing Cholangitis Revenue by Countries
7.1 Asia-Pacific Primary Sclerosing Cholangitis Revenue by Countries (2013-2018)
7.2 China Primary Sclerosing Cholangitis Revenue and Growth Rate (2013-2018)
7.3 Japan Primary Sclerosing Cholangitis Revenue and Growth Rate (2013-2018)
7.4 Korea Primary Sclerosing Cholangitis Revenue and Growth Rate (2013-2018)
7.5 India Primary Sclerosing Cholangitis Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Primary Sclerosing Cholangitis Revenue and Growth Rate (2013-2018)
8 South America Primary Sclerosing Cholangitis Revenue by Countries
8.1 South America Primary Sclerosing Cholangitis Revenue by Countries (2013-2018)
8.2 Brazil Primary Sclerosing Cholangitis Revenue and Growth Rate (2013-2018)
8.3 Argentina Primary Sclerosing Cholangitis Revenue and Growth Rate (2013-2018)
8.4 Colombia Primary Sclerosing Cholangitis Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Primary Sclerosing Cholangitis by Countries
9.1 Middle East and Africa Primary Sclerosing Cholangitis Revenue by Countries (2013-2018)
9.2 Saudi Arabia Primary Sclerosing Cholangitis Revenue and Growth Rate (2013-2018)
9.3 UAE Primary Sclerosing Cholangitis Revenue and Growth Rate (2013-2018)
9.4 Egypt Primary Sclerosing Cholangitis Revenue and Growth Rate (2013-2018)
9.5 Nigeria Primary Sclerosing Cholangitis Revenue and Growth Rate (2013-2018)
9.6 South Africa Primary Sclerosing Cholangitis Revenue and Growth Rate (2013-2018)
10 Global Primary Sclerosing Cholangitis Market Segment by Type
10.1 Global Primary Sclerosing Cholangitis Revenue and Market Share by Type (2013-2018)
10.2 Global Primary Sclerosing Cholangitis Market Forecast by Type (2018-2023)
10.3 Type I Revenue Growth Rate (2013-2023)
10.4 Type II Revenue Growth Rate (2013-2023)
11 Global Primary Sclerosing Cholangitis Market Segment by Application
11.1 Global Primary Sclerosing Cholangitis Revenue Market Share by Application (2013-2018)
11.2 Primary Sclerosing Cholangitis Market Forecast by Application (2018-2023)
11.3 Hospital Revenue Growth (2013-2018)
11.4 Clinics Revenue Growth (2013-2018)
11.5 Other Revenue Growth (2013-2018)
12 Global Primary Sclerosing Cholangitis Market Size Forecast (2018-2023)
12.1 Global Primary Sclerosing Cholangitis Market Size Forecast (2018-2023)
12.2 Global Primary Sclerosing Cholangitis Market Forecast by Regions (2018-2023)
12.3 North America Primary Sclerosing Cholangitis Revenue Market Forecast (2018-2023)
12.4 Europe Primary Sclerosing Cholangitis Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Primary Sclerosing Cholangitis Revenue Market Forecast (2018-2023)
12.6 South America Primary Sclerosing Cholangitis Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Primary Sclerosing Cholangitis Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Primary Sclerosing Cholangitis Picture
Table Product Specifications of Primary Sclerosing Cholangitis
Table Global Primary Sclerosing Cholangitis and Revenue (Millio
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
